Kristin Dortch, | |
6335 Hospital Pkwy Ste Ll17, Duluth, GA 30097-1549 | |
(404) 778-8311 | |
Not Available |
Full Name | Kristin Dortch |
---|---|
Gender | Female |
Speciality | Anesthesiology - Critical Care Medicine |
Location | 6335 Hospital Pkwy Ste Ll17, Duluth, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1578263943 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | RN249338 (Georgia) | Secondary |
207LC0200X | Anesthesiology - Critical Care Medicine | RN249338 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kristin Dortch, 3055 Level Grove Way, Dacula, GA 30019-1831 Ph: () - | Kristin Dortch, 6335 Hospital Pkwy Ste Ll17, Duluth, GA 30097-1549 Ph: (404) 778-8311 |
News Archive
A simple, precise and inexpensive method for cutting DNA to insert genes into human cells could transform genetic medicine, making routine what now are expensive, complicated and rare procedures for replacing defective genes in order to fix genetic disease or even cure AIDS.
Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of common stock at a price of $6.00 per share.
The Devex Development Newswire reports on the upcoming G20 summit, which will take place in Los Cabos, Mexico, on June 18-19. The news service writes, "In a letter issued May 25, European Council President Herman Van Rompuy and European Commission President Jose Manuel Barroso noted the European Union's four priority areas at the summit," which are growth and employment, strengthening the International Monetary Fund, reforming the financial system, and food security and the G20's development work.
An initiative that will appear on the November ballot in Oregon would expand a state prescription drug program to cover all residents without drug coverage, the Oregonian reports.
GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.
› Verified 6 days ago